To enable tumor-targeted delivery of anti–4-1BB, we formulated a DBCO-functionalized anti–4-1BB mAb (DBCO–anti–4-1BB) that could react with the azide group on Maz. The gene discussed is TNFRSF9; the disease is neoplasm.